Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices traded up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 47 points (0.3%) at 18,019 as of Friday, Feb. 13, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,931 issues advancing vs. 1,153 declining with 128 unchanged.

The Diversified Services industry as a whole closed the day up 0.6% versus the S&P 500, which was up 0.4%. Top gainers within the Diversified Services industry included

China Yida

(

CNYD

), up 7.3%,

Bioanalytical Systems

(

BASI

), up 9.6%,

Wilhelmina International

(

WHLM

), up 2.1%,

Internet Patents

(

PTNT

), up 2.5% and

VirtualScopics

(

VSCP

), up 5.8%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Wilhelmina International

(

WHLM

) is one of the companies that pushed the Diversified Services industry higher today. Wilhelmina International was up $0.12 (2.1%) to $5.79 on heavy volume. Throughout the day, 4,240 shares of Wilhelmina International exchanged hands as compared to its average daily volume of 1,900 shares. The stock ranged in a price between $5.57-$5.79 after having opened the day at $5.65 as compared to the previous trading day's close of $5.67.

Wilhelmina International has a market cap of $33.6 million and is part of the services sector. Shares are down 5.5% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

Bioanalytical Systems

(

BASI

) was up $0.18 (9.6%) to $2.06 on heavy volume. Throughout the day, 35,904 shares of Bioanalytical Systems exchanged hands as compared to its average daily volume of 5,200 shares. The stock ranged in a price between $1.87-$2.08 after having opened the day at $1.88 as compared to the previous trading day's close of $1.88.

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in North America, the Pacific Rim, Europe, and internationally. Bioanalytical Systems has a market cap of $17.6 million and is part of the services sector. Shares are up 0.0% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Bioanalytical Systems a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Bioanalytical Systems as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on BASI go as follows:

  • BIOANALYTICAL SYSTEMS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has suffered a declining pattern earnings per share over the past two years. During the past fiscal year, BIOANALYTICAL SYSTEMS INC swung to a loss, reporting -$0.15 versus $0.09 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Life Sciences Tools & Services industry. The net income has significantly decreased by 260.3% when compared to the same quarter one year ago, falling from $0.25 million to -$0.40 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, BIOANALYTICAL SYSTEMS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for BIOANALYTICAL SYSTEMS INC is currently lower than what is desirable, coming in at 34.63%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -6.29% is significantly below that of the industry average.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 36.07%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 266.66% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here:

Bioanalytical Systems Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

China Yida

(

CNYD

) was another company that pushed the Diversified Services industry higher today. China Yida was up $0.17 (7.3%) to $2.50 on light volume. Throughout the day, 109 shares of China Yida exchanged hands as compared to its average daily volume of 2,800 shares. The stock ranged in a price between $2.50-$2.50 after having opened the day at $2.50 as compared to the previous trading day's close of $2.33.

China Yida Holding Co., together with its subsidiaries, is engaged in the tourism and advertisement businesses in the People's Republic of China. The company operates through two segments, Advertisement and Tourism. China Yida has a market cap of $9.1 million and is part of the services sector. Shares are unchanged year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate China Yida a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates China Yida as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on CNYD go as follows:

  • CHINA YIDA HOLDING CO has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, CHINA YIDA HOLDING CO swung to a loss, reporting -$4.24 versus $0.06 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Media industry. The net income has significantly decreased by 249.6% when compared to the same quarter one year ago, falling from -$3.63 million to -$12.68 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Media industry and the overall market, CHINA YIDA HOLDING CO's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has decreased to -$2.52 million or 19.92% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 47.05%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 59.18% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here:

China Yida Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.